Author:
Chiang Ryan S.,Muir Andrew J.
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108:175–81.
https://doi.org/10.2105/AJPH.2017.304132
.
2. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;31(373):2599–607.
https://doi.org/10.1056/NEJMoa1512610
.
3. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67:263–71.
https://doi.org/10.1016/j.jhep.2017.03.039
.
4. American Association for the Study of Liver Disease and Infectious Diseases Society of America (2017) Recommendations for testing, managing, and treating hepatitis C.
http://www.hcvguidelines.org
. Accessed 6 Dec 2018.
5. Center for Disease Control (2015) Sharps safety for healthcare setting.
https://www.cdc.gov/sharpssafety/index.html
. Accessed 8 Dec 2018.